and indicates noncompliance
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
Someone reads the 24.2 percent figure, wants it now, and ramps both compounds hard in the first fortnight
Peggion C, Panetta V, Lastella L, Formaggio F, Ricci A, Oancea S, et al
FDA identified possible immunogenicity risks from aggregation and peptide-related impurities and proposed not adding either defined TB-500 substance to the 503A Bulks List
Our supplemental vitamin injectionssuch as B12, Vitamin D, and other nutrient blendsoffer a quick and efficient way to support overall wellness and mental clarity